tisagenlecleucel,venetoclax,nelarabine,bortezomib,Rituximab,Imatinib,Idarubicin
abbvie,takeda,roche,Novartis
['leusm', 'elara', 'venetoclax', 'bortezomib', 'nelarabine', 'borte']
congress| #ash22 nicola goekbuget, reported the updated results of the risk-adapted, mrd-stratified gmall trial 08/2013 in 281 adult pts with t- all/lbl. os=78% for total cohort. thymic t-all was shown to be a low-risk subgroup. #allsm #leusm 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm